RxSight, Inc. Reports Third Quarter 2026 Results
Q3 revenue fell 19% to $24.6M on competition; GAAP net loss widened to $(0.39)/sh from $(0.24); gross margin 73.6% vs 79.9%.
What this release says
RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from a year earlier, with a larger net loss than the prior year. Gross margin fell to 73.6% from 79.9%, and the company's cash position of $254.7 million includes a $60 million payment received in connection with the Alcon collaboration. For a shareholder, the quarter shows weaker sales and profitability, though the company is restructuring costs and leaning on the Alcon partnership.
Key figures
- Q3 total revenue
- $24.6 million
- Q3 Light Adjustable Lens units
- 23,128 units
- Cash and short-term investments
- $254.7 million
- Q3 net loss
- $(16.2) million
- Q3 gross margin
- 73.6%
- Q3 total cost and expenses
- $43.1 million
Positive for shareholders
- Cash, cash equivalents and short-term investments stood at $254.7 million at quarter end.
- The company says it cut operating expenses in its core business through a restructuring.
- The Alcon collaboration's initial 120-day period is now complete and described as off to a strong start.
Negative for shareholders
- Revenue fell 19% from the prior-year period, which the company attributes to ongoing competitive pressures.
- Gross margin dropped to 73.6% from 79.9%, reflecting higher inventory reserves and inventory costs.
- The net loss widened to $(16.2) million from $(9.8) million a year earlier.
- Revenue recognized under the Alcon collaboration was minimal in the quarter.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Light Adjustable Lens (LAL):
- RxSight's intraocular lens that can be adjusted after surgery to refine a patient's vision.
- Adjusted net loss:
- A non-GAAP measure equal to net loss excluding stock-based compensation, which the company uses to show operating performance.
- Inventory reserves:
- Amounts set aside to cover possible losses on unsold or slow-moving inventory, which reduce gross margin when increased.
FAQ
How much did RxSight's revenue change in the third quarter of 2026?
Total revenue was $24.6 million, down 19% from the prior-year period, which the company primarily attributes to ongoing competitive pressures.
Why did RxSight's gross margin decline?
The company said gross margin fell to 73.6% mainly because of higher inventory reserves and higher inventory costs for LAL and LDD, partly offset by favorable product mix.
How much cash does RxSight have after the Alcon payment?
As of September 30, 2026, RxSight reported cash, cash equivalents and short-term investments of $254.7 million, including the $60 million received in the third quarter from the Alcon collaboration.
Historical context for RXST
Across the 24 sessions after earlier RXST headlines, the stock closed higher 13 times and lower 11 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RXST | SPY |
|---|---|---|---|
| Oct 26, 2026 | RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules | -1.8% | +0.7% |
| Oct 21, 2026 | RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3 | +0.4% | +0.5% |
| Oct 19, 2026 | RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation | +4.0% | +0.4% |
| Oct 16, 2026 | K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world | -3.4% | -1.1% |
| Aug 27, 2026 | RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference | +3.6% | +0.7% |
| Aug 6, 2026 | RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook | -3.3% | -0.2% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- Listed since
- 2021
Follow RXST and get a push notification the moment its next story breaks.